How B2B Brands Pivoted Overnight To Meet Customer Demands

 

Over the past year and a half, companies have had to make a lot of changes and quickly. For B2B brands, this is no different, as brands have had to pivot overnight to meet their customers’ demands.

Giving insights on this episode of the podcast is Christian Yungbluth, Director of Global Marketing at Hatco Corporation, a leader in creating innovative ideas for the foodservice industry: bold innovations in equipment that improves efficiency, reliability, and profits. He talked to Host Tyler Kern about how B2B brands have had to pivot overnight to meet their customers’ demands.

Hatco works with a variety of industries. This allows them to see firsthand how companies have had to adapt over the past year. “2020 had a largely negative impact on the entire industry foodservice wise, but also on the manufacturing side,” Yungbluth said. “On the foodservice side, obviously, restaurants were shut down.”

Restaurants have to shift to a BOPIS model, which saw employees have minimal contact with customers. In order to adapt, they had to install heated shelves, lights, and other infrastructure that allowed restaurants to function during the pandemic. Now, restaurants have reopened to in-person seating, so they’ve had to pivot to a new model that includes distancing and masking. But, that doesn’t mean customers are quick to go back to dine-in services.

“There’s still a great deal of pick-up going on now,” Yungbluth said. “You see new trends with how restaurants choose to interface with the marketplace.”

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More